Immunotherapeutics / Bioelectronic Medicine / Contract Manufacturing
Strategic Profile
Tivic has evolved into a diversified immunotherapeutics and health technology company. In January 2026, the company presented Entolimod at a BARDA TechWatch meeting with U.S. defense and health agencies, showcasing clinical results and manufacturing readiness, with BARDA requesting expedited follow-up to discuss potential inclusion in the Strategic National Stockpile.
Cyborg Score Rationale
With a market cap of only $2.16M and stock trading at $0.84, the company faces severe liquidity and market confidence challenges. While the BARDA engagement represents a significant validation opportunity for Entolimod, extreme financial distress and micro-cap status indicate elevated execution risk.
Top Insights
January 2026 BARDA TechWatch presentation of Entolimod with request for expedited follow-up discussions for Strategic National Stockpile inclusion
Strategic shift from consumer bioelectronic medicine (ClearUP) toward immunotherapeutics and contract manufacturing
Stock has declined 87% from all-time high of $11,050 (Nov 2021) to $1.47 low (Nov 2025)
Recent acquisition of Scorpius Holdings manufacturing and development assets signals vertical integration strategy for biologic production
Named Competitors
Traditional sinus relief products — OTC decongestants and saline sprays for sinus congestion
Radiation countermeasure programs — Government-funded ARS and radiation protection research
Recent Developments
(January 2026) BARDA TechWatch meeting with presentation of Entolimod clinical results and manufacturing readiness
(December 2025) Acquisition of Scorpius Holdings assets for manufacturing and development capabilities